Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on May 17, 2013. The report addresses the receipt of regulatory approval for a strategic agreement with Walgreen Co. and Alliance Boots GmbH, involving a long-term pharmaceutical distribution contract and an equity investment.
Key Financial Metrics and Guidance
The filing reiterates fiscal year 2013 guidance and provides projections for fiscal year 2014 related to the new partnership:
- Fiscal 2013 Revenue Growth: Expected in the range of 11% to 13%.
- Fiscal 2013 Adjusted Diluted EPS: Expected in the lower half of the $3.04 to $3.14 range from continuing operations. This excludes expenses related to the Walgreens/Alliance Boots relationship, warrant issuance, and expected LIFO charges from inventory onboarding.
- Fiscal 2014 Partnership Impact: The Walgreens and Alliance Boots agreements are expected to contribute an incremental $25 billion in revenues and approximately $0.20 in adjusted earnings per share. These figures exclude amortization of transaction expenses, warrant costs, non-recurring costs, potential LIFO charges, and net of start-up expenses.
The filing does not provide specific current period revenue, profit, cash flow, debt, or liquidity figures, as it focuses on forward-looking guidance and event disclosure.
Material Changes and Strategic Developments
The primary material change is the regulatory approval of the equity stake purchase agreement announced on March 19, 2013. Key terms include:
- Equity Rights: Walgreens and Alliance Boots have the right to purchase up to 7% of the Company's fully diluted equity in the open market.
- Warrants: The Company granted warrants exercisable for an aggregate of 16% of fully diluted equity, allocated equally between the two partners.
- Tranche 1: 8% of equity, strike price $51.50, exercisable for six months beginning March 2016.
- Tranche 2: 8% of equity, strike price $52.50, exercisable for six months beginning March 2017.
- Board Representation: Walgreens may appoint one director upon the partners acquiring a 5% equity stake, and a second director upon full exercise of the first warrant tranche.
- Standstill Agreement: Partners agreed not to acquire additional equity beyond the terms of the agreement, subject to certain exceptions.
Outlook, Risks, and Contingencies
Management commentary emphasizes the acceleration of growth in specialty and manufacturer services businesses domestically and internationally through the partnership. The filing notes specific contingencies affecting the financial guidance:
- LIFO Charges: Guidance excludes potential LIFO charges associated with onboarding additional branded inventory.
- Transaction Costs: Fiscal 2014 projections exclude amortization of expenses related to the transaction and warrant issuance.
- Regulatory Status: The filing confirms that regulatory approval has been received, removing a key contingency for the deal's execution.
Investor Verification Checklist
- Verify the exact terms of the standstill agreement and pre-emption rights regarding future equity acquisitions.
- Monitor the timing and conditions for the exercise of the two warrant tranches in 2016 and 2017.
- Assess the magnitude of the excluded LIFO charges and transaction costs to understand the impact on reported earnings versus adjusted guidance.
- Confirm the progress of the 10-year primary pharmaceutical distribution contract implementation with Walgreens.